Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 20/20 | 1.00 |
| ▸ | AKR1B10 | O60218 | 1/20 | 1.00 |
| ▸ | AKR1A1 | P14550 | 1/20 | 1.00 |
| ▸ | GLO1 | Q04760 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Zopolrestat SCHEMBL29353641 | 1.00 | AKR1B1 (1.00) | AKR1B1AKR1B10AKR1A1GLO1 | |
| Zopolrestat SCHEMBL8505122 | 1.00 | AKR1B1 (1.00) | AKR1B1AKR1B10AKR1A1GLO1 | |
| Zopolrestat SCHEMBL8129027 | 0.99 | AKR1B1 (0.98) | AKR1B1AKR1B10AKR1A1GLO1 | |
| Zopolrestat SCHEMBL7185596 | 0.95 | AKR1B1 (0.90) | AKR1B1AKR1B10AKR1A1GLO1 | |
| Zopolrestat SCHEMBL7179887 | 0.93 | AKR1B1 (0.87) | AKR1B1AKR1B10AKR1A1GLO1 | |
| Zopolrestat SCHEMBL7180777 | 0.93 | AKR1B1 (0.87) | AKR1B1AKR1B10AKR1A1GLO1 | |
| Zopolrestat SCHEMBL15939730 | 0.92 | AKR1B1 (0.84) | AKR1B1AKR1B10AKR1A1GLO1 | |
| Zopolrestat SCHEMBL7565103 | 0.92 | AKR1B1 (0.84) | AKR1B1AKR1B10AKR1A1GLO1 | |
| Zopolrestat SCHEMBL8129830 | 0.91 | AKR1B1 (0.83) | AKR1B1AKR1B10AKR1A1GLO1 | |
| Zopolrestat SCHEMBL15939751 | 0.90 | AKR1B1 (0.81) | AKR1B1AKR1B10AKR1A1GLO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3491 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250177348-A1 | Methods for Fructokinase Meditation of Alcohol Craving and Alcohol Induced Liver Disease | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE | 2025-06-05 | — | — | US | claimed |
| US-20240374693-A1 | TREATMENT AND DETECTION OF INHERITED NEUROPATHIES AND ASSOCIATED DISORDERS | UNIVERSITY OF ROCHESTER | 2024-11-14 | — | — | US | claimed |
| US-12083168-B2 | Treatment and detection of inherited neuropathies and associated disorders | UNIVERSITY OF MIAMI (US) | 2024-09-10 | — | — | US | claimed |
| WO-2024053761-A1 | COMPOSITION FOR PROMOTING MYOBLAST PROLIFERATION AND DIFFERENTIATION CONTAINING ALDOSE REDUCTASE INHIBITOR | 애니머스큐어 주식회사 | 2024-03-14 | — | — | WO | claimed |
| US-20240033263-A1 | COMBINATION OF ALDOSE REDUCTASE INHIBITORS AND PROBENECID FOR THE TREATMENT OF DIABETIC COMPLICATIONS | MYLARI Banavara (US) | 2024-02-01 | — | — | US | claimed |
| US-20240003908-A1 | POLYOL BIOMARKERS FOR CONGENITAL DISORDERS OF GLYCOSYLATION | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2024-01-04 | — | — | US | claimed |
| US-20230346782-A1 | COMPOSITIONS AND METHODS FOR TREATING GALACTOSEMIA | BARCLAYS BANK PLC (GB) | 2023-11-02 | — | — | US | claimed |
| US-20230293642-A9 | TREATMENT AND DETECTION OF INHERITED NEUROPATHIES AND ASSOCIATED DISORDERS | UNIVERSITY OF ROCHESTER | 2023-09-21 | — | — | US | claimed |
| EP-4244243-A1 | POLYOL BIOMARKERS FOR CONGENITAL DISORDERS OF GLYCOSYLATION | Mayo Foundation for Medical Education and Research (US) | 2023-09-20 | — | — | EP | claimed |
| US-20230058134-A1 | ALDOSE REDUCTASE INHIBITORS FOR THE TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME, ACUTE LUNG INFLAMMATION/INJURY, CARDIAC INJURY AND ANTI-VIRAL THERAPY | BARCLAYS BANK PLC (GB) | 2023-02-23 | — | — | US | claimed |
| WO-1999002189-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING AN ALDOSE REDUCTASE INHIBITOR AND AN ACE INHIBITOR | ZENECA LIMITED (GB) | 1999-01-21 | — | — | WO | claimed |
| EP-0880964-A2 | Aldose reductase inhibition in preventing or reversing diabetic cardiomyopathy | PFIZER INC. (US) | 1998-12-02 | — | — | EP | claimed |
| US-5834466-A | ADMINISTERING ALDOSE REDUCTASE INHIBITOR, NICOTINIC ACID OR METHYLENE BLUE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1998-11-10 | — | — | US | claimed |
| WO-1998022114-A1 | A METHOD FOR PROMOTING TISSUE REPAIR | DUMEX-ALPHARMA A/S (DK) | 1998-05-28 | — | — | WO | claimed |
| EP-0801569-A1 | METHOD FOR PROTECTING THE HEART FROM ISCHEMIA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1997-10-22 | — | — | EP | claimed |
| EP-0792643-A1 | Use of an aldose reductase inhibitor for reducing non-cardiac tissue damage | PFIZER INC. (US) | 1997-09-03 | — | — | EP | claimed |
| WO-1996019225-A9 | METHOD FOR PROTECTING THE HEART FROM ISCHEMIA | — | 1996-09-19 | — | — | WO | claimed |
| WO-1996019225-A1 | METHOD FOR PROTECTING THE HEART FROM ISCHEMIA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1996-06-27 | — | — | WO | claimed |
| US-5391551-A | Method of lowering blood lipid levels | PFIZER INC. (US) | 1995-02-21 | — | — | US | claimed |
| EP-0624369-A1 | Method of lowering blood lipid levels | PFIZER INC. (US) | 1994-11-17 | — | — | EP | claimed |